Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.50 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 8/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130274 | 0.98 | RBP4 (0.51) | RBP4SMOALDH1A1HPGDGAA | |
| SCHEMBL16862022 | 0.84 | SMO (0.54) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL17761042 | 0.84 | RBP4 (0.49) | RBP4SMOALDH1A1HPGDMGLL | |
| Tert-Butyl Formate SCHEMBL27964275 | 0.84 | RBP4 (0.47) | RBP4SMOALDH1A1HPGDGAA | |
| SCHEMBL12181507 | 0.83 | L3MBTL3 (0.55) | RBP4 | |
| SCHEMBL23213437 | 0.83 | HPGD (0.49) | RBP4SMOALDH1A1HPGDNPC1 | |
| SCHEMBL28740942 | 0.83 | RBP4 (0.48) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL694233 | 0.83 | RBP4 (0.48) | RBP4SMOALDH1A1HPGDMGLL | |
| Ethylene SCHEMBL8381035 | 0.80 | RBP4 (0.46) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL7135868 | 0.79 | ALDH1A1 (0.42) | RBP4ALDH1A1HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | RBP4 3866/4885SMO 4214/4885ALDH1A1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.